Accordingly, it has been suggested that the administration of antioxidants and NOX4 inhibitors may be considered effective disease-modifying therapeutic interventions for SSc and other fibrotic disorders, including pulmonary and liver fibrosis [106,107,108,109,110,111,112,113,114,115,116,117,118,119]. The gene discussed is NOX4; the disease is systemic sclerosis.